Mirum Pharmaceuticals Inc (nasdaq:MIRM) Share Price

Company Profile

Business description
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Contact
989 East Hillsdale Boulevard
Suite 300
Foster CityCA94404
USA
T: +1 650 667-4085
https://www.mirumpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
355

Recommended

Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.

Malik Ahmed Khan, CFA | 08 January 2026

Wagering continues to be challenged in Australia.

Angus Hewitt, CFA | 08 January 2026

Rising inflation is the fly in the ointment.

Simonelle Mody | 08 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,045.90	27.80	-0.31%
CAC 40	8,292.46	49.00	0.59%
DAX 40	25,145.09	17.63	0.07%
Dow JONES (US)	49,266.11	270.03	0.55%
FTSE 100	10,084.22	39.53	0.39%
HKSE	26,231.79	82.48	0.32%
NASDAQ	23,480.02	104.26	-0.44%
Nikkei 225	51,939.89	822.63	1.61%
NZX 50 Index	13,696.25	20.61	-0.15%
S&P 500	6,921.46	0.53	0.01%
S&P/ASX 200	8,717.80	29.10	-0.33%
SSE Composite Index	4,120.43	37.45	0.92%